Print

Praecis Pharmaceuticals Incorporated (PRCS) Receives The Cerep Award For Research Related To Its Investigational Drug Candidate, PPI-2458  
10/24/2006 11:43:58 AM

WALTHAM, Mass.--(BUSINESS WIRE)--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it received the Cerep Award for Research with the greatest therapeutic potential at the 14th International Inflammation Research Association (IRA) Conference held in Cambridge, Maryland last week. The award was given to PRAECIS for its presentation entitled “Disease-modifying activity in a model of rheumatoid arthritis with an orally available inhibitor of methionine aminopeptidase type-2, PPI-2458,” which was delivered by William Westlin, Ph.D., Senior Vice President, Preclinical Research. Dr. Westlin presented preclinical data that provide the scientific rationale for studying the investigational compound PPI-2458 as a targeted molecular therapy for rheumatoid arthritis. The presentation may be viewed on the Company’s website (http://www.praecis.com) in the “Investors” section, under “Presentations.”
//-->